Objective
The objective of this Integrated Project Genostem is to establish a European international scientific leadership for stem cell regenerative medicine in the field of connective tissue disorders. Autologous adult Mesenchymal Stem Cells (MSCs) are optimal candidates to serve as the building blocks for the engineering of connective tissues being multipotential stem cells that give rise to osteoblasts, chondrocytes and tenocytes, muscle cells and adipocytes. Genostem will compare different tissue sources of MSCs and isolate subsets in order to obtain undifferentiated MSCs, committed MSCs at early stage of differentiation, progeny blocked at specific differentiation stage and fully differentiated progeny. Genostem will study the complete MSC gene product repertoire using genomic and proteomic analysis that should provide with the molecules and pathways potentially operative for the maintenance and differentiation of stem cells. Genostem will develop innovative technologies to generate biodegradable matrices, scaffolds and microcarriers that bind pharmacologically active proteins and allow their delivery in a controlled way; these biomaterials will allow engineering MSCs such as to obtain optimal repair of the target injured tissue. Genostem will improve methods for gene transfer using original virus or non-viral delivery systems in order to carry out gain (gene transfer) and loss (siRNA transfer) of function studies. Genostem will develop transplantation models of MSCs mimicking human pathological processes operative in bone cartilage and tendon diseases. The final goal is to develop clinical trials using MSCs, in bone, cartilage and tendon disorders, in partnership with SMEs and regulatory bodies for the scale up of safe procedures, taking advantage of the experience already acquired by one of the partner in clinical trials using cultured muscle cells.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicinetransplantation
- engineering and technologyindustrial biotechnologybiomaterials
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback.
You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Topic(s)
Call for proposal
FP6-2002-LIFESCIHEALTH
See other projects for this call
Funding Scheme
IP - Integrated ProjectCoordinator
PARIS
France
See on map
Participants (23)
LONDON
See on map
PARIS
See on map
ZURICH
See on map
JERUSALEM
See on map
ROME
See on map
TIMISOARA
See on map
BERLIN
See on map
HAIFA
See on map
MADRID
See on map
HERAKLION
See on map
BRAGA
See on map
PARIS
See on map
ZURICH
See on map
RENNES
See on map
MIRIBEL
See on map
ECUBLENS
See on map
LUND
See on map
BERLIN
See on map
BRAUNSCHWEIG
See on map
PARIS
See on map
MÜNCHEN
See on map
CAEN
See on map
TOURS
See on map